busulfan has been researched along with EBV Infections in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 9.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 5.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| " The graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate." | 4.12 | Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. ( Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, S | 1 |
| Chen, J | 2 |
| Liu, Z | 1 |
| Xiao, J | 1 |
| Jiang, F | 1 |
| Liu, X | 1 |
| Sun, Y | 1 |
| Kawashiri, A | 1 |
| Nakagawa, SI | 1 |
| Ishiguro, C | 1 |
| Mochizuki, K | 1 |
| Maeda, Y | 1 |
| Kurokawa, T | 1 |
| Wang, J | 1 |
| Zhao, J | 1 |
| Fei, X | 1 |
| Yin, Y | 1 |
| Cheng, H | 1 |
| Zhang, W | 1 |
| Gu, J | 1 |
| Yang, F | 1 |
| Yang, Y | 1 |
| Xue, S | 1 |
| Tian, Z | 1 |
| He, J | 1 |
| Zhang, S | 1 |
| Wang, X | 1 |
| Marinho-Dias, J | 1 |
| Lobo, J | 1 |
| Henrique, R | 1 |
| Baldaque, I | 1 |
| Pinho-Vaz, C | 1 |
| Regadas, L | 1 |
| Branca, R | 1 |
| Campilho, F | 1 |
| Campos, A | 1 |
| Medeiros, R | 1 |
| Sousa, H | 1 |
| Bossuyt, X | 1 |
| Mariën, G | 1 |
| Uyttebroeck, A | 1 |
| Bitan, M | 1 |
| Or, R | 1 |
| Shapira, MY | 1 |
| Mador, N | 1 |
| Resnick, IB | 1 |
| Saleh, N | 1 |
| Weinberger, KM | 1 |
| Samuel, S | 1 |
| Schechter, E | 1 |
| Slavin, S | 1 |
| Wolf, DG | 1 |
| Deeg, HJ | 1 |
| Storer, BE | 1 |
| Boeckh, M | 1 |
| Martin, PJ | 1 |
| McCune, JS | 1 |
| Myerson, D | 1 |
| Heimfeld, S | 1 |
| Flowers, ME | 1 |
| Anasetti, C | 1 |
| Doney, KC | 1 |
| Hansen, JA | 1 |
| Kiem, HP | 1 |
| Nash, RA | 1 |
| O'Donnell, PV | 1 |
| Radich, JP | 1 |
| Sandmaier, BM | 1 |
| Scott, BL | 1 |
| Sorror, ML | 1 |
| Warren, EH | 1 |
| Witherspoon, RP | 1 |
| Woolfrey, A | 1 |
| Appelbaum, FR | 1 |
| Storb, R | 1 |
| Zhu, KE | 1 |
| Li, JP | 1 |
| Zhang, T | 1 |
| Zhong, J | 1 |
| Taketani, T | 1 |
| Kikuchi, A | 1 |
| Inatomi, J | 1 |
| Hanada, R | 1 |
| Kawaguchi, H | 1 |
| Ida, K | 1 |
| Oh-Ishi, T | 1 |
| Arai, T | 1 |
| Kishimoto, H | 1 |
| Yamamoto, K | 1 |
1 trial available for busulfan and EBV Infections
| Article | Year |
|---|---|
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cause of Death; Child; Chron | 2006 |
8 other studies available for busulfan and EBV Infections
| Article | Year |
|---|---|
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Cocktail Conditioning Regimen for the Treatment of Pediatric Patients with Chronic Active Epstein-Barr Virus: A Retrospective Observational Study.
Topics: Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Epstein-Barr Virus Infections; | 2022 |
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.
Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; H | 2022 |
A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Cystitis; Cytarabine; Cytomegalovirus Infections; Dru | 2018 |
Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Epstein-Barr Virus Infection | 2018 |
A transient IgE monoclonal protein in a child.
Topics: Adrenoleukodystrophy; Antibodies, Monoclonal; Busulfan; Child; Cyclosporine; Epstein-Barr Virus Infe | 2011 |
Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.
Topics: Antilymphocyte Serum; Busulfan; Epstein-Barr Virus Infections; Guillain-Barre Syndrome; Humans; Male | 2004 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antig | 2007 |
Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chronic Dise | 2002 |